EP4185306A4 - Notch-signalhemmer zur behandlung von adipositas und stoffwechselerkrankungen - Google Patents

Notch-signalhemmer zur behandlung von adipositas und stoffwechselerkrankungen Download PDF

Info

Publication number
EP4185306A4
EP4185306A4 EP21846580.5A EP21846580A EP4185306A4 EP 4185306 A4 EP4185306 A4 EP 4185306A4 EP 21846580 A EP21846580 A EP 21846580A EP 4185306 A4 EP4185306 A4 EP 4185306A4
Authority
EP
European Patent Office
Prior art keywords
metabolic disorders
treating obesity
notch signaling
signaling inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21846580.5A
Other languages
English (en)
French (fr)
Other versions
EP4185306A1 (de
Inventor
Meng Deng
Di HUANG
Shihuan Kuang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of EP4185306A1 publication Critical patent/EP4185306A1/de
Publication of EP4185306A4 publication Critical patent/EP4185306A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21846580.5A 2020-07-23 2021-07-23 Notch-signalhemmer zur behandlung von adipositas und stoffwechselerkrankungen Pending EP4185306A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055410P 2020-07-23 2020-07-23
PCT/US2021/042867 WO2022020658A1 (en) 2020-07-23 2021-07-23 Notch signaling inhibitors for treating obesity and metabolic disorders

Publications (2)

Publication Number Publication Date
EP4185306A1 EP4185306A1 (de) 2023-05-31
EP4185306A4 true EP4185306A4 (de) 2024-11-06

Family

ID=79729001

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21846580.5A Pending EP4185306A4 (de) 2020-07-23 2021-07-23 Notch-signalhemmer zur behandlung von adipositas und stoffwechselerkrankungen

Country Status (4)

Country Link
US (1) US20230277549A1 (de)
EP (1) EP4185306A4 (de)
CN (1) CN116234898A (de)
WO (1) WO2022020658A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025265140A1 (en) * 2024-06-21 2025-12-26 Adipo Therapeutics, Llc Processes for preparing nanoparticles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069826A1 (en) * 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
US20070225273A1 (en) * 2006-03-27 2007-09-27 Alexander Flohr Malonamide derivatives
US8741889B2 (en) * 2008-01-11 2014-06-03 Hoffmann-La Roche Inc Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
EP2932966A1 (de) * 2014-04-16 2015-10-21 Novartis AG Gammasekretasehemmer zur Behandlung von Atemwegserkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121457A1 (en) * 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
US20150258052A1 (en) * 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
HUE051713T2 (hu) * 2014-03-14 2021-03-29 Alltech Inc Szelenoorganikus vegyületeket tartalmazó készítmények és ezek alkalmazása
WO2017075136A1 (en) * 2015-10-27 2017-05-04 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069826A1 (en) * 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
US20070225273A1 (en) * 2006-03-27 2007-09-27 Alexander Flohr Malonamide derivatives
US8741889B2 (en) * 2008-01-11 2014-06-03 Hoffmann-La Roche Inc Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
EP2932966A1 (de) * 2014-04-16 2015-10-21 Novartis AG Gammasekretasehemmer zur Behandlung von Atemwegserkrankungen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUNHUI JIANG ET AL: "Dibenzazepine-Loaded Nanoparticles Induce Local Browning of White Adipose Tissue to Counteract Obesity", MOLECULAR THERAPY, vol. 25, no. 7, 1 July 2017 (2017-07-01), US, pages 1718 - 1729, XP055580549, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.05.020 *
HUANG DI ET AL: "Evaluation of Clinical Candidates of [gamma]-Secretase Inhibitors: Effects on Notch Inhibition and Promoting Beige Adipogenesis and Mitochondrial Biogenesis", ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 37, no. 10, 4 September 2020 (2020-09-04), XP037237334, ISSN: 0724-8741, [retrieved on 20200904], DOI: 10.1007/S11095-020-02916-7 *
PENGPENG BI ET AL: "Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity", NATURE MEDICINE, vol. 20, no. 8, 1 August 2014 (2014-08-01), New York, pages 911 - 918, XP055580950, ISSN: 1078-8956, DOI: 10.1038/nm.3615 *
See also references of WO2022020658A1 *

Also Published As

Publication number Publication date
CN116234898A (zh) 2023-06-06
US20230277549A1 (en) 2023-09-07
EP4185306A1 (de) 2023-05-31
WO2022020658A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
EP4058018A4 (de) Verfahren zum behandeln von lsd1-verwandten krankheiten und störungen mit lsd1-inhibitoren
IL308193A (en) RAS inhibitors
GB202001344D0 (en) Ras Inhibitors
EP3746135A4 (de) Verfahren und verbindungen zur behandlung von erkrankungen
EP4359074A4 (de) Verfahren und kits zur auslösung von sättigung und behandlung von stoffwechselerkrankungen
EP3801744A4 (de) Verfahren und vorrichtung zur behandlung von schlafbedingten atemstörungen
WO2020150552A3 (en) Methods of treating cartilage disorders through inhibition of clk and dyrk
IL294594A (en) Methods of treating pemphigus
EP3802621B8 (de) Zusammensetzung und anwendung von argininabreicherungsmitteln für krebs, adipositas, stoffwechselerkrankungen und verwandte komplikationen und komorbiditäten
EP4352079A4 (de) Zusammensetzungen und verfahren zur behandlung neurofibromatischer erkrankungen
EP3891122A4 (de) Decarboxylase-inhibitoren zur behandlung von morbus parkinson
EP4185306A4 (de) Notch-signalhemmer zur behandlung von adipositas und stoffwechselerkrankungen
CA3261972A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP4003336A4 (de) Calpain-inhibitoren und ihre verwendungen zur behandlung von neurologischen erkrankungen
ES3059224T3 (en) Compounds for prevention and treatment of obesity and related disorders
HK40091262A (en) Inhibitors for use in treating liver disorders
EP3969005A4 (de) Verfahren und zusammensetzungen zur behandlung von fettleibigkeit und / oder hauterkrankungen
HK40110376A (en) Compositions and methods for treating neurofibromatic disorders
CA3305450A1 (en) Rock2 inhibitors in the treatment of obesity
HK40053043A (en) Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
HK40110336A (en) Assessing and treating obesity
CA3306904A1 (en) Hdac6-selective inhibitor for use in the treatment of obesity, cardiovascular and metabolic diseases and disorders
AU2024355858A1 (en) Hdac6-selective inhibitor for use in the treatment of obesity, cardiovascular and metabolic diseases and disorders
HK40126588A (en) Methods and systems for treating disease using an atr/chk1 signaling pathway inhibitor
CA3273146A1 (en) Compositions and methods for treating obesity

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0035380000

Ipc: A61K0031192000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20240624BHEP

Ipc: A61K 8/00 20060101ALI20240624BHEP

Ipc: A61P 3/04 20060101ALI20240624BHEP

Ipc: A61K 31/4164 20060101ALI20240624BHEP

Ipc: A61K 31/335 20060101ALI20240624BHEP

Ipc: A61P 3/08 20060101ALI20240624BHEP

Ipc: A61K 35/38 20150101ALI20240624BHEP

Ipc: C12N 5/071 20100101ALI20240624BHEP

Ipc: A61K 31/5513 20060101ALI20240624BHEP

Ipc: A61K 31/55 20060101ALI20240624BHEP

Ipc: A61K 31/4245 20060101ALI20240624BHEP

Ipc: A61K 31/417 20060101ALI20240624BHEP

Ipc: A61K 31/192 20060101AFI20240624BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20241009

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20241003BHEP

Ipc: A61K 8/00 20060101ALI20241003BHEP

Ipc: A61P 3/04 20060101ALI20241003BHEP

Ipc: A61K 31/4164 20060101ALI20241003BHEP

Ipc: A61K 31/335 20060101ALI20241003BHEP

Ipc: A61P 3/08 20060101ALI20241003BHEP

Ipc: A61K 35/38 20150101ALI20241003BHEP

Ipc: C12N 5/071 20100101ALI20241003BHEP

Ipc: A61K 31/5513 20060101ALI20241003BHEP

Ipc: A61K 31/55 20060101ALI20241003BHEP

Ipc: A61K 31/4245 20060101ALI20241003BHEP

Ipc: A61K 31/417 20060101ALI20241003BHEP

Ipc: A61K 31/192 20060101AFI20241003BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250926